3-Dodecan-6-ylpyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Dodecan-6-ylpyridine
• 英文别名: 3-dodecan-6-ylpyridine
• 化学式: C₁₇H₂₉N
• 分子量: 247.4
• InChiKey: XLXXWWRQXZJTAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  18
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS
  申请人：Pipeline Therapeutics, Inc.

  公开号：US20210161889A1

  公开（公告）日：2021-06-03

  Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M 1 (mAChR M 1 ); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

  本文提供了作为肌胆碱受体M1（mAChR M1）拮抗剂有用的化合物；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与肌胆碱受体功能障碍相关的神经和精神疾病的方法。
• Suprametallogels and uses thereof
  申请人：Massachusetts Institute of Technology

  公开号：US10023536B2

  公开（公告）日：2018-07-17

  The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

  本发明提供了通过过渡金属-配体（如式（A）的钯（II）-、镍（II）-或铁（II）-配体）配位和结点自组装形成的纳米结构（如纳米球和纳米桨叶）。本公开还提供了超分子复合物，其中包括通过二价连接剂 Y 连接的纳米结构。所提供的超分子复合物能够形成凝胶（如水凝胶）。凝胶是超金属凝胶，在不牺牲自愈合的情况下表现出优异的机械性能，并显示出较高的坚固性和储存模量。本公开进一步提供了包括纳米结构或超分子复合物和可选药剂（如小分子）的组合物（如凝胶），其中纳米结构和超分子复合物的纳米结构分子可包裹并缓慢释放药剂。纳米结构、超分子复合物和组合物可作为超吸收材料用于向受试者、组织或细胞递送药剂，以及治疗疾病（如遗传性疾病、增殖性疾病（如癌症或良性肿瘤）、血液病、神经系统疾病、胃肠道疾病（如肝脏疾病、脾脏疾病、呼吸系统疾病等））、肝病）、脾脏疾病、呼吸系统疾病（如肺病）、疼痛、泌尿生殖系统疾病、肌肉骨骼疾病、传染病、炎症性疾病、自身免疫性疾病、精神疾病或代谢紊乱）。
• Bicyclic compounds as pesticides
  申请人：BAYER CROPSCIENCE AKTIENGESELLSCHAFT

  公开号：US10294243B2

  公开（公告）日：2019-05-21

  The present application relates to novel bicyclic compounds, to their use for controlling animal pests and to processes and intermediates for their preparation.

  本申请涉及新型双环化合物、它们在控制动物害虫方面的用途以及制备它们的工艺和中间体。
• Urea derivatives and uses thereof
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US10316022B2

  公开（公告）日：2019-06-11

  The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.

  本发明提供了式(I)-(III)中任一项的新型化合物及其药物组合物。本发明还提供了由式（I）-（III）化合物及其药物组合物组成的具有粘液渗透性的颗粒（如纳米颗粒）。本发明还提供了使用本发明化合物及其药物组合物治疗和/或预防与异常或病理性血管生成和/或生长因子（如血管内皮生长因子（VEGF））异常信号转导有关的疾病的方法和试剂盒，如增殖性疾病（如、如增殖性疾病（如癌症、良性肿瘤、炎症性疾病、自身免疫性疾病）和眼部疾病（如黄斑变性、青光眼、糖尿病视网膜病变、视网膜母细胞瘤、水肿、葡萄膜炎、干眼症、睑缘炎和手术后炎症）。
• Compounds and uses thereof
  申请人：Kala Pharmaceuticals, Inc.

  公开号：US10351570B2

  公开（公告）日：2019-07-16

  The present invention provides novel compounds of any one of Formulae (I)-(IV), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of Formulae (I)-(IV) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.

  本发明提供了式(I)-(IV)中任一项的新型化合物及其药物组合物。本发明还提供了由式（I）-（IV）中任意一种化合物及其药物组合物组成的具有粘液渗透性的颗粒（如纳米颗粒）。本发明还提供了使用本发明化合物及其药物组合物治疗和/或预防与异常或病理性血管生成和/或生长因子信号通路异常信号转导（如......血管内皮生长因子）相关疾病的方法和试剂盒、血管内皮生长因子（VEGF））相关的疾病，如增殖性疾病（如癌症、良性肿瘤、炎症性疾病、自身免疫性疾病）和眼部疾病（如黄斑变性、青光眼、糖尿病视网膜病变、视网膜母细胞瘤、水肿、葡萄膜炎、干眼症、睑缘炎和手术后炎症）。